With the evolution of India's disease burden as well as its pharmaceutical industry, the need for clinical trials has increased. This report analyses the prospects and challenges of clinical trials in India, focusing on new chemical entities and new drugs, and proposes actionable policy recommendations for the Indian drug regulatory landscape.